Base de dados : MEDLINE
Pesquisa : C04.700 [Categoria DeCS]
Referências encontradas : 2072 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 208 ir para página                         

  1 / 2072 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29443732
[Au] Autor:Lou S; Wang Y; Yu Z; Guan K; Kan Q
[Ad] Endereço:Department of Pharmacology.
[Ti] Título:Curcumin induces apoptosis and inhibits proliferation in infantile hemangioma endothelial cells via downregulation of MCL-1 and HIF-1α.
[So] Source:Medicine (Baltimore);97(7):e9562, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Curcumin has been used as an alternative medicine for the treatment of infantile hemangiomas (IHs); however, the mechanism underlying the effectiveness of curcumin in IHs remains largely unclear. METHODS: In this study, we isolated primary human hemangioma endothelial cells (HemECs) from fresh surgical specimens of 3 patients. We treated HemECs by curcumin and investigated the alterations in proliferative and apoptotic signaling pathways with cell counting kit-8, flow cytometry, western blotting, immunofluorescence, and real-time polymerase chain reaction. RESULTS AND CONCLUSION: We found that curcumin potently inhibited proliferation in HemECs, achieving low-micromolar IC50 (the half maximal inhibitory concentration) value. We also observed that treatment with curcumin induced apoptosis in HemECs, as evidenced by positively Annexin-V-FITC staining, caspase-3 activation, and cleavage of poly(adenosine diphosphate-ribose) polymerase (PARP) in the treated cells. Moreover, we showed that curcumin suppressed the expression of antiapoptotic protein myeloid cell leukemia-1 (MCL-1), hypoxia-inducible factor 1α (HIF-1α), and vascular endothelial growth factor (VEGF).Altogether, our study suggests that the effectiveness of curcumin in IHs may be associated with its potent antiproliferative and apoptotic activities in HemECs.
[Mh] Termos MeSH primário: Antineoplásicos/farmacologia
Curcumina/farmacologia
Hemangioma Capilar/tratamento farmacológico
Subunidade alfa do Fator 1 Induzível por Hipóxia/efeitos dos fármacos
Proteína de Sequência 1 de Leucemia de Células Mieloides/efeitos dos fármacos
Síndromes Neoplásicas Hereditárias/tratamento farmacológico
[Mh] Termos MeSH secundário: Apoptose/efeitos dos fármacos
Proliferação Celular/efeitos dos fármacos
Pré-Escolar
Regulação para Baixo
Células Endoteliais/efeitos dos fármacos
Hemangioma Capilar/genética
Seres Humanos
Subunidade alfa do Fator 1 Induzível por Hipóxia/metabolismo
Masculino
Proteína de Sequência 1 de Leucemia de Células Mieloides/metabolismo
Síndromes Neoplásicas Hereditárias/genética
Transdução de Sinais/efeitos dos fármacos
Fator A de Crescimento do Endotélio Vascular/efeitos dos fármacos
Fator A de Crescimento do Endotélio Vascular/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (HIF1A protein, human); 0 (Hypoxia-Inducible Factor 1, alpha Subunit); 0 (MCL1 protein, human); 0 (Myeloid Cell Leukemia Sequence 1 Protein); 0 (Vascular Endothelial Growth Factor A); IT942ZTH98 (Curcumin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180215
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009562


  2 / 2072 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29266077
[Au] Autor:Committee on Gynecologic Practice
[Ti] Título:ACOG Committee Opinion No. 727: Cascade Testing: Testing Women for Known Hereditary Genetic Mutations Associated With Cancer.
[So] Source:Obstet Gynecol;131(1):e31-e34, 2018 01.
[Is] ISSN:1873-233X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:"Cascade testing" refers to the performance of genetic counseling and testing in blood relatives of individuals who have been identified with specific genetic mutations. Testing protocols and other interventions may save lives and improve health and quality of life for these family members. Obstetrician-gynecologists should know who is eligible for cascade testing and should use all available resources to ensure that cascade testing is offered and occurs in a timely manner. Despite the clear health benefits for specific populations and individuals, obstetrician-gynecologists should be aware of the potential barriers to cascade testing and should know which options can help patients overcome those barriers. Such barriers, however, may be overcome with health care provider awareness and participation in local and state initiatives to improve implementation of cascade testing. Resources (available within federal and state agencies, professional societies, and in advocacy and community groups) are critical to the successful implementation of cascade testing. This Committee Opinion focuses specifically on cascade testing and the role of the obstetrician-gynecologist in clinical and public health efforts to increase identification of women with hereditary cancer syndromes.
[Mh] Termos MeSH primário: Aconselhamento Genético
Predisposição Genética para Doença
Síndromes Neoplásicas Hereditárias/genética
Síndromes Neoplásicas Hereditárias/prevenção & controle
Cuidado Pré-Concepcional/métodos
Qualidade de Vida
[Mh] Termos MeSH secundário: Comitês Consultivos/normas
Feminino
Testes Genéticos
Ginecologia/normas
Seres Humanos
Mutação/genética
Obstetrícia/normas
Guias de Prática Clínica como Assunto
Gravidez
Medição de Risco
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180116
[Lr] Data última revisão:
180116
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171222
[St] Status:MEDLINE
[do] DOI:10.1097/AOG.0000000000002457


  3 / 2072 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29266071
[Ti] Título:ACOG Committee Opinion No. 727 Summary: Cascade Testing: Testing Women For Known Hereditary Genetic Mutations Associated With Cancer.
[So] Source:Obstet Gynecol;131(1):194-195, 2018 Jan.
[Is] ISSN:1873-233X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:"Cascade testing" refers to the performance of genetic counseling and testing in blood relatives of individuals who have been identified with specific genetic mutations. Testing protocols and other interventions may save lives and improve health and quality of life for these family members. Obstetrician-gynecologists should know who is eligible for cascade testing and should use all available resources to ensure that cascade testing is offered and occurs in a timely manner. Despite the clear health benefits for specific populations and individuals, obstetrician-gynecologists should be aware of the potential barriers to cascade testing and should know which options can help patients overcome those barriers. Such barriers, however, may be overcome with health care provider awareness and participation in local and state initiatives to improve implementation of cascade testing. Resources (available within federal and state agencies, professional societies, and in advocacy and community groups) are critical to the successful implementation of cascade testing. This Committee Opinion focuses specifically on cascade testing and the role of the obstetrician-gynecologist in clinical and public health efforts to increase identification of women with hereditary cancer syndromes.
[Mh] Termos MeSH primário: Predisposição Genética para Doença/prevenção & controle
Testes Genéticos/métodos
Neoplasias dos Genitais Femininos/genética
Síndromes Neoplásicas Hereditárias/diagnóstico
Síndromes Neoplásicas Hereditárias/genética
Guias de Prática Clínica como Assunto
[Mh] Termos MeSH secundário: Comitês Consultivos
Medicina Baseada em Evidências
Feminino
Aconselhamento Genético/organização & administração
Neoplasias dos Genitais Femininos/prevenção & controle
Seres Humanos
Programas de Rastreamento/métodos
Mutação/genética
Gravidez
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180108
[Lr] Data última revisão:
180108
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171222
[St] Status:MEDLINE
[do] DOI:10.1097/AOG.0000000000002451


  4 / 2072 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29191275
[Au] Autor:Torphy RJ; Schulick RD
[Ad] Endereço:Department of Surgery, University of Colorado, 12631 East 17th Avenue, C-302, Aurora, CO 80045, USA.
[Ti] Título:Screening of Patients at Risk for Familial Pancreatic Cancer: What Is Beneficial?
[So] Source:Surg Clin North Am;98(1):25-35, 2018 Feb.
[Is] ISSN:1558-3171
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Family history is a significant risk factor for developing pancreatic cancer and this hereditary risk can be secondary to familial cancer predisposition syndromes, hereditary pancreatitis, or familial pancreatic cancer. Certain high-risk individuals are recommended to undergo screening for pancreatic cancer with endoscopic ultrasound or MRI/magnetic resonance retrograde cholangiopancreatography because of the potential to identify and curatively resect precursor lesions. The management of suspicious lesions identified on screening high-risk individuals is also discussed.
[Mh] Termos MeSH primário: Carcinoma
Detecção Precoce de Câncer
Predisposição Genética para Doença
Síndromes Neoplásicas Hereditárias
Neoplasias Pancreáticas
[Mh] Termos MeSH secundário: Carcinoma/diagnóstico
Carcinoma/epidemiologia
Carcinoma/genética
Testes Genéticos
Seres Humanos
Incidência
Síndromes Neoplásicas Hereditárias/diagnóstico
Síndromes Neoplásicas Hereditárias/epidemiologia
Síndromes Neoplásicas Hereditárias/genética
Neoplasias Pancreáticas/diagnóstico
Neoplasias Pancreáticas/epidemiologia
Neoplasias Pancreáticas/genética
Medição de Risco
Estados Unidos/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171211
[Lr] Data última revisão:
171211
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171202
[St] Status:MEDLINE


  5 / 2072 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28960912
[Au] Autor:van Engelen K; Villani A; Wasserman JD; Aronoff L; Greer MC; Tijerin Bueno M; Gallinger B; Kim RH; Grant R; Meyn MS; Malkin D; Druker H
[Ad] Endereço:Genetics and Genome Biology Program, The Hospital for Sick Children Research Institute, Toronto, Ontario, Canada.
[Ti] Título:DICER1 syndrome: Approach to testing and management at a large pediatric tertiary care center.
[So] Source:Pediatr Blood Cancer;65(1), 2018 Jan.
[Is] ISSN:1545-5017
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: To expand the current knowledge of DICER1 syndrome and to propose criteria for genetic testing based on experience at a pediatric tertiary care center. PROCEDURE: This study involved a retrospective chart review of the 78 patients (47 probands and 31 family members) seen in the Cancer Genetics Program at The Hospital for Sick Children (SickKids) who were offered genetic testing for DICER1. RESULTS: Of 47 probands offered genetic testing for DICER1, 46 pursued testing: 11 (23.9%) carried a pathogenic variant and one proband (2.1%) carried a missense variant of uncertain significance with evidence for pathogenicity. Thirty-one family members of variant-positive probands were offered testing: eight of the 25 who agreed to testing carried their familial variant (32.0%). Overall, 20 patients were identified to have a variant in DICER1 (eight males, 12 females). Of these, 13 (65.0%) presented with clinical manifestations associated with the syndrome. The most common lesions were pleuropulmonary blastoma (PPB) (five of 20 patients, 25.0%) and pineoblastoma (three of 20 patients, 15.0%). The average age at which individuals were diagnosed with a primary neoplasm was 5.2 years (range 0.8-20 years, median 3.0). Surveillance at our institution, with a median follow-up time of 23 months, has identified PPB in two asymptomatic individuals. These lesions were identified at early stages, thus potentially reducing treatment-related morbidity and mortality. CONCLUSION: This study further delineates the DICER1 syndrome phenotype and demonstrates the feasibility of a DICER1 syndrome surveillance protocol for the early detection of tumors.
[Mh] Termos MeSH primário: Neoplasias Encefálicas/genética
Síndromes Neoplásicas Hereditárias/genética
Glândula Pineal
Pinealoma/genética
Blastoma Pulmonar/genética
[Mh] Termos MeSH secundário: Adolescente
Adulto
Neoplasias Encefálicas/metabolismo
Neoplasias Encefálicas/patologia
Criança
Pré-Escolar
Feminino
Seguimentos
Seres Humanos
Lactente
Recém-Nascido
Masculino
Síndromes Neoplásicas Hereditárias/mortalidade
Síndromes Neoplásicas Hereditárias/patologia
Pinealoma/mortalidade
Pinealoma/patologia
Blastoma Pulmonar/mortalidade
Blastoma Pulmonar/patologia
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171201
[Lr] Data última revisão:
171201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170930
[St] Status:MEDLINE
[do] DOI:10.1002/pbc.26720


  6 / 2072 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28834056
[Au] Autor:Postema FAM; Hopman SMJ; Hennekam RC; Merks JHM
[Ad] Endereço:Department of Pediatric Oncology, Emma Children's Hospital, Academic Medical Center, Amsterdam, The Netherlands.
[Ti] Título:Consequences of diagnosing a tumor predisposition syndrome in children with cancer: A literature review.
[So] Source:Pediatr Blood Cancer;65(1), 2018 Jan.
[Is] ISSN:1545-5017
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Up to 8.5% of children with cancer have a genetic cause for their cancer: a tumor predisposition syndrome (TPS). Diagnosing a TPS is of great importance, as it may have major consequences for clinical care. Patients with TPSs require specific monitoring and management. We present an overview of the cancer-related and noncancer-related consequences for the 36 most common TPSs.
[Mh] Termos MeSH primário: Síndromes Neoplásicas Hereditárias/genética
[Mh] Termos MeSH secundário: Adolescente
Criança
Pré-Escolar
Feminino
Predisposição Genética para Doença
Seres Humanos
Lactente
Masculino
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171201
[Lr] Data última revisão:
171201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170824
[St] Status:MEDLINE
[do] DOI:10.1002/pbc.26718


  7 / 2072 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28766837
[Au] Autor:Saskin A; de Kock L; Sabbaghian N; Apellaniz-Ruiz M; Bozkurt C; Bouron-Dal Soglio D; Foulkes WD
[Ad] Endereço:Department of Medical Genetics, Research Institute of the McGill University Health Centre, Montréal, Québec, Canada.
[Ti] Título:A case of neuroblastoma in DICER1 syndrome: Chance finding or noncanonical causation?
[So] Source:Pediatr Blood Cancer;65(1), 2018 Jan.
[Is] ISSN:1545-5017
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:DICER1 syndrome is an inherited disorder associated with at least a dozen rare, mainly pediatric-onset tumors. Its characterization remains incomplete. Some studies suggested that neuroblastoma (NB) may be involved in this syndrome. Here, we describe the case of a 14-year-old female presenting with a multinodular goiter (MNG) and a collision tumor composed of NB and cystic nephroma (CN). She is a carrier of a deleterious germline mutation in exon 23 of DICER1 and harbored different somatic mutations in the CN and MNG. However, no second hit was found in the NB, questioning its status as a DICER1-related tumor.
[Mh] Termos MeSH primário: RNA Helicases DEAD-box/genética
Éxons
Mutação em Linhagem Germinativa
Bócio Nodular/genética
Síndromes Neoplásicas Hereditárias/genética
Neuroblastoma/genética
Ribonuclease III/genética
[Mh] Termos MeSH secundário: Adolescente
Feminino
Bócio Nodular/enzimologia
Seres Humanos
Síndromes Neoplásicas Hereditárias/enzimologia
Neuroblastoma/enzimologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
EC 3.1.26.3 (DICER1 protein, human); EC 3.1.26.3 (Ribonuclease III); EC 3.6.4.13 (DEAD-box RNA Helicases)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171201
[Lr] Data última revisão:
171201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170803
[St] Status:MEDLINE
[do] DOI:10.1002/pbc.26715


  8 / 2072 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29023082
[Au] Autor:Tidman AS
[Ti] Título:Be vigilant for skin manifestations of inherited cancer syndromes.
[So] Source:Practitioner;261(1800):23-7, 2017 01.
[Is] ISSN:0032-6518
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:More than 200 hereditary cancer susceptibility syndromes have been described, and it is thought that they account for 5-10% of all cancers. Many have dermatological manifestations (usually lesions, occasionally rashes) which frequently precede other systemic pathology. Dermatological signs are usually non-specific and often trivial in appearance, making their significance easy to overlook and a clinical diagnosis challenging. Histological examination is often required to differentiate lesions. They are usually benign and pathologically unrelated to the primary tumours, with the exception of the atypical moles of the dysplastic naevus syndrome, and may present simply as a cosmetic problem for the patient. However, a number of cancer syndromes exhibit an increased risk of developing malignant skin lesions. For instance, Gorlin syndrome (nevoid basal cell carcinoma syndrome) which typically results in the development of multiple basal cell carcinomas, within the first few decades of life. The majority of cancer syndromes with skin signs are inherited in an autosomal dominant pattern demonstrating complete penetrance before the age of 70. Once a cancer syndrome has been diagnosed, the cornerstone of management is frequent surveillance for the early detection and treatment of malignancy. Genetic testing and counselling should be offered to family members.
[Mh] Termos MeSH primário: Síndromes Neoplásicas Hereditárias/diagnóstico
Síndromes Neoplásicas Hereditárias/genética
Anormalidades da Pele/diagnóstico
Anormalidades da Pele/genética
[Mh] Termos MeSH secundário: Fatores Etários
Síndrome do Nevo Basocelular/genética
Feminino
Predisposição Genética para Doença
Seres Humanos
Masculino
Síndromes Neoplásicas Hereditárias/complicações
Cistos Odontogênicos/genética
Fatores de Risco
Pele/patologia
Anormalidades da Pele/complicações
Neoplasias Cutâneas/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171026
[Lr] Data última revisão:
171026
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171013
[St] Status:MEDLINE


  9 / 2072 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29020592
[Au] Autor:Lemery S; Keegan P; Pazdur R
[Ad] Endereço:From the Office of Hematology and Oncology Products (S.L., P.K.) and the Oncology Center of Excellence (R.P.), Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD.
[Ti] Título:First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication.
[So] Source:N Engl J Med;377(15):1409-1412, 2017 Oct 12.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Anticorpos Monoclonais Humanizados/uso terapêutico
Antineoplásicos/uso terapêutico
Biomarcadores Tumorais
Neoplasias Encefálicas/tratamento farmacológico
Neoplasias Colorretais/tratamento farmacológico
Neoplasias do Sistema Digestório/tratamento farmacológico
Aprovação de Drogas
Instabilidade de Microssatélites
Síndromes Neoplásicas Hereditárias/tratamento farmacológico
Receptor de Morte Celular Programada 1/antagonistas & inibidores
[Mh] Termos MeSH secundário: Adulto
Antígeno B7-H1/metabolismo
Neoplasias da Mama/tratamento farmacológico
Criança
Neoplasias Colorretais/patologia
Feminino
Seres Humanos
Masculino
Metástase Neoplásica/tratamento farmacológico
Receptor de Morte Celular Programada 1/metabolismo
Estados Unidos
United States Food and Drug Administration
Neoplasias Urogenitais/tratamento farmacológico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Monoclonal, Humanized); 0 (Antineoplastic Agents); 0 (B7-H1 Antigen); 0 (Biomarkers, Tumor); 0 (CD274 protein, human); 0 (PDCD1 protein, human); 0 (Programmed Cell Death 1 Receptor); DPT0O3T46P (pembrolizumab)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171012
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMp1709968


  10 / 2072 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28991567
[Au] Autor:Katabathina VS; Menias CO; Prasad SR
[Ad] Endereço:Department of Radiology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA. Electronic address: katabathina@uthscsa.edu.
[Ti] Título:Imaging and Screening of Hereditary Cancer Syndromes.
[So] Source:Radiol Clin North Am;55(6):1293-1309, 2017 Nov.
[Is] ISSN:1557-8275
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:There is a wide spectrum of mendelian disorders that predispose patients to an increased risk of benign as well as malignant tumors. Hereditary cancer syndromes are characterized by the early onset of diverse, frequently advanced malignancies in specific organ systems in multiple family members, posing significant challenges to diagnosis and management. A better understanding of the genetic abnormalities and pathophysiology that underlie these disorders has led to contemporary paradigms to screen, allowing early diagnosis, and has improved targeted therapies to aid in management. This article reviews select hereditary cancer syndromes with an emphasis on imaging-based screening and surveillance strategies.
[Mh] Termos MeSH primário: Diagnóstico por Imagem/métodos
Síndromes Neoplásicas Hereditárias/diagnóstico por imagem
[Mh] Termos MeSH secundário: Colonoscopia/métodos
Seres Humanos
Imagem por Ressonância Magnética/métodos
Tomografia Computadorizada por Raios X/métodos
Ultrassonografia/métodos
Imagem Corporal Total/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171010
[St] Status:MEDLINE



página 1 de 208 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde